Condition: Kidney Transplantation · Mycophenolate Mofetil · Sponsor: Mayo Clinic
The purpose of this research is to determine the safety and efficacy of withdrawing MMF (Mycophenolate Mofetil) in kidney transplant recipients who are 55 years or older at the time of receiving a kidney transplant. We are comparing them to patients who receive the standard of care Mycophenolate Mofetil.
This description comes directly from the study's public registry record.
Nong Yowe Braaten, LPN · 507-266-6893 · braaten.nong@mayo.edu
Esma Kesik, M.D. · 507-284-4562 · kesik.esma@mayo.edu
Always discuss trial participation with your own doctor first.
| Mayo Clinic | Phoenix, Arizona, United States | Recruiting |
| Mayo Clinic | Jacksonville, Florida, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06568549